Ovid Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
OVID
- Investments
-
3
- Share Price
-
$2.54
- (As of Friday Closing)
Ovid Therapeutics General Information
Description
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Contact Information
Website
www.ovidrx.comCorporate Office
- Hudson Commons
- 441 9th Avenue, 14th Floor
- New York, NY 10001
- United States
Corporate Office
- Hudson Commons
- 441 9th Avenue, 14th Floor
- New York, NY 10001
- United States
Ovid Therapeutics Timeline
Ovid Therapeutics Stock Performance
As of 13-Nov-2026, Ovid Therapeutics’s stock price is $2.54. Its current market cap is $479M with 189M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.54 | $2.55 | $1.18 - $3.10 | $479M | 189M | 1.92M | -$0.23 |
Ovid Therapeutics Financials Summary
As of 30-Sep-2026, Ovid Therapeutics has a trailing 12-month revenue of $1.45M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 381,788 | 104,236 | 18,665 | 156,817 |
| Revenue | 1,453 | 7,252 | 566 | 392 |
| EBITDA | (43,031) | (17,141) | (29,720) | (56,671) |
| Net Income | (43,114) | (17,414) | (26,433) | (52,339) |
| Total Assets | 222,244 | 150,934 | 92,167 | 144,027 |
| Total Debt | 12,354 | 13,419 | 14,755 | 16,002 |
Ovid Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ovid Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Ovid Therapeutics Comparisons
Industry
Financing
Details
Ovid Therapeutics Competitors (26)
One of Ovid Therapeutics’s 26 competitors is CuraSen, a Venture Capital-Backed company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| CSL Behring | Corporation | King Of Prussia, PA | ||||
| Phaxiam | Formerly VC-backed | Lyon, France | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom |
Ovid Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ovid Therapeutics Patents
Ovid Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260335330-A1 | Fused amino pyrimidine compounds for treatment of cancer | Pending | 21-Apr-2025 | ||
| WO-2026226558-A1 | Fused amino pyrimidine compounds for treatment of cancer | Pending | 21-Apr-2025 | ||
| US-20260242382-A1 | Fused amino pyrimidine compounds for treatment of overweight and obesity | Pending | 14-Feb-2025 | ||
| WO-2026174139-A1 | Fused amino pyrimidine compounds for treatment of overweight and obesity | Pending | 14-Feb-2025 | ||
| US-20260130878-A1 | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain | Pending | 12-Nov-2024 | A61K31/196 |
Ovid Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ovid Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ovid Therapeutics Investments (3)
Ovid Therapeutics’s most recent deal was a Later Stage VC with Healx for . The deal was made on 01-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Healx | 01-Aug-2024 | Later Stage VC | Discovery Tools (Healthcare) | ||
| Graviton BioScience | 04-Dec-2023 | Early Stage VC | Drug Discovery | ||
| Gensaic | 06-Sep-2022 | Early Stage VC | Drug Delivery |
Ovid Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.19 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Ovid Therapeutics FAQs
-
When was Ovid Therapeutics founded?
Ovid Therapeutics was founded in 2014.
-
Where is Ovid Therapeutics headquartered?
Ovid Therapeutics is headquartered in New York, NY.
-
What is the size of Ovid Therapeutics?
Ovid Therapeutics has 23 total employees.
-
What industry is Ovid Therapeutics in?
Ovid Therapeutics’s primary industry is Biotechnology.
-
Is Ovid Therapeutics a private or public company?
Ovid Therapeutics is a Public company.
-
What is Ovid Therapeutics’s stock symbol?
The ticker symbol for Ovid Therapeutics is OVID.
-
What is the current stock price of Ovid Therapeutics?
As of 13-Nov-2026 the stock price of Ovid Therapeutics is $2.54.
-
What is the current market cap of Ovid Therapeutics?
The current market capitalization of Ovid Therapeutics is $479M.
-
What is Ovid Therapeutics’s current revenue?
The trailing twelve month revenue for Ovid Therapeutics is $1.45M.
-
Who are Ovid Therapeutics’s competitors?
CuraSen, Neurogene, CSL Behring, Phaxiam, and Orchard Therapeutics are some of the 26 competitors of Ovid Therapeutics.
-
What is Ovid Therapeutics’s annual earnings per share (EPS)?
Ovid Therapeutics’s EPS for 12 months was -$0.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
